B-cells in multiple sclerosis

International MS Journal

Volumn 13, Issue 3, 2006, Pages 84-90

  Duddy, Martin ^a   Bar Or, A ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

B cells; Immune response; Multiple sclerosis; Pathogenesis; Treatment strategies

Indexed keywords

ANTIBODY; ANTIGEN; CD20 ANTIGEN; GLUCOCORTICOID; IMMUNOGLOBULIN; MITOXANTRONE; NATALIZUMAB; OLIGOCLONAL BAND; RITUXIMAB;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CYTOLOGY; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOMODULATION; MEMORY CELL; MULTIPLE SCLEROSIS; PATHOGENESIS; PLASMA CELL; RELAPSE; REMYELINIZATION; REVIEW; TISSUE INJURY; TISSUE REPAIR;

AUTOANTIBODIES; B-LYMPHOCYTES; BIOLOGICAL RESPONSE MODIFIERS; DOWN-REGULATION; HUMANS; IMMUNOGLOBULIN M; INTERFERON-BETA; INTERLEUKIN-10; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS;

EID: 33845395095     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinoting disease. J Neuroimmunol 2001; 112: 1-14.
2. Ziemssen T, Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev 2005; 4: 460-467.
3. Corcione A, Aloisi F, Serafini B, Capello E, Mancardi GL, Pistoia V et al. B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmun Rev 2005; 4: 549-554.
4. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23: 487-513.
5. Goodnow CC, Cyster JG, Hartley SB, Bell SE, Cooke MP, Healy JI et al. Self-tolerance checkpoints in B lymphocyte development. Adv Immunol 1995; 59: 279-368.
6. Baumgarth N. A two-phase model of B-cell activation. Immunol Rev 2000; 176: 171-180.
7. Fayette J, Durand I, Bridon JM, Arpin C, Dubois B, Caux C et al. Dendritic cells enhance the differentiation of naive B cells into plasma cells in vitro. Scand J Immunol 1998; 48: 563-570.
8. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Not Immunol 2000; 1: 475-482.
9. Schultze JL, Michalak S, Lowne J, Wang A, Gilleece MH, Gribben JG et al. Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. J Exp Med 1999; 189: 1-12.
10. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172: 3422-3427.
11. MacLennan IC. Germinal centers. Annu Rev Immunol 1994; 12: 117-139.
12. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J. Clonal expansion and somatic hypermutation of Vh genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998; 102: 1045-1050.
13. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163: 5133-5144.
14. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000; 37: 1141-1149.
15. Villar LM, Sadaba MC, Roldan E, Masjuan J, Gonzalez-Porque P, Villarrubia N et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-194.
16. Esiri MM. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 1977; ii: 478.
17. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170: 4497-4505.
18. Niino M, Bodner C, Simard M-L, Alatab S, Gano D, Kim HJ et al. Natalizumab effects on immune responses in multiple sclerosis. Ann Neurol 2006; 59: 748-754.
19. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesions. Brain 1997; 120: 1461-1483.
20. Broadwell RD, Baker BJ, Ebert PS, Hickey WF. Allografts of CNS tissues possess a blood brain barrier: III. Neuropathological, methodological and immunological considerations. Microsc Res Tech 1994; 27: 471-494.
21. Prineas JW. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979; 203: 1123-1125.
22. Jurewicz A, Matysiak M, Tybor K, Selmaj K. TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3. Brain 2003; 126: 1358-1370.
23. Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128: 1667-1676.
24. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005; 23: 367-386.
25. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-2202.
26. Mallison SM, Smith JP, Schenkein HA, Tew JG. Accumulation of plasma cells in inflamed sites: effects of antigen, nonspecific microbial activators, and chronic inflammation, infect Immun 1991; 59: 4019-4025.
27. Prineas JW, Wright RG. Macrophages., lymphocytes and plasma cells in the perivascular compartment in chronic muftiple sclerosis, Lab Invest 1978; 38: 409-421.
28. Walsh MJ, Tourtelotte WW, Roman J, Dreyer W. Immunoglobulin G, A, and M-clonal restriction in multiple sclerosis cerebrospinal fluid and serum-analysis by two-dimensional electrophoresis. Clin Immunol Immunopathol 1985; 35: 313-327.
29. O'Connor KC, Chitnis T. Griffin DE. Piyasirisilp S, Bar-Or A, Khoury S et al. Myelin basic protein-reactive autoantibodies in the serum and CSF of multiple sclerosis patients ore characterized by low-affinity interactions. J Neuroimmunol 2003; 136: 140-148.
30. O'Connor KC, Appel H, Bregoli L, Call ME, Catz I, Chan JA et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005; 175: 1974-1982.
31. Genain CP, Cannetlla, B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-175.
32. Lucchinetti C, Bruck W, Parisi J. Scheithauer B, Rodriguez M, Lassmann H, Heterogeneity of multiple sclerosis lesions: implication s for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
33. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-468.
34. Kerschensleiner M, Gallmeier E, Behrens L, Leal W, Misgeid T, Klinkert WE et al. Activated human T celis, B cells, and monocyfes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective rote of inflammation? J Exp Med 1999; 189: 865-870.
35. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM, B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950.
36. Rodriguez M, Lennon VA. Immunogiobuiins promote remyelination in the central nervous system. Ann Neurol 1990; 27: 12-17.
37. Monson NL. Crovens PD. Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62: 258-264.
38. Warren KG, Catz I, Jeffrey VM, Carroll D. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein, and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci 1986; 13: 25-30,
39. Frequin ST, Barkhof F, Lamers KJ, Hommes OR, Borm GF. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and affer treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand 1992; 86: 291-297.
40. Crockard AD, Treacy MT, Droogan AG, McNeill TA, Hawkins SA. Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis. Multiple Sclerosis 1995; 1: 20-24.
41. Jiang H, Milo R, Swoveland P. Johnson KP, Panitch H, Dhib-Jalbut S. Interferon beta-1b reduces Interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol 1995; 61: 17-25.
42. Gene K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by Interferon beta-1b therapy. J Clin Invest 1997; 99: 2004-2071.
43. Uu Z, Pelfrey CM, Cotleur A, Lee JC, Rudick RA. Immunomodulatory effects of Interferon beta-1a in multiple sclerosis. J Neuroirnmunol 2001; 112: 153-162.
44. Kim HJ, Ifergan I, Antel JR Seguin R, Duddy M, Lapierre Y et al. Type 2 monocyte and microglio differentiation mediated by glattrarner acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144-7153,
45. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152-158.
46. Humle Jorgensen S, Sorensen PS. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci 2005; 233: 61-05.
47. Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunogiobulins in demyelinating diseases. Arch Neurol 1999; 56: 661-663.